Potential role of lymphadenectomy in advanced ovarian cancer: A combined exploratory analysis of three prospectively randomized phase III multicenter trials

Journal of Clinical Oncology

Volumn 28, Issue 10, 2010, Pages 1733-1739

  Du Bois, Andreas ^a   Reuss, Alexander ^a   Harter, Philipp ^a   Pujade Lauraine, Eric ^a   Ray Coquard, Isabelle ^a   Pfisterer, Jacobus ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIRUBICIN; PACLITAXEL; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; EXPLORATORY RESEARCH; FEMALE; HUMAN; HUMAN TISSUE; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; SURVIVAL TIME; COMPARATIVE STUDY; EVALUATION; LYMPH NODE METASTASIS; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MORTALITY; MULTICENTER STUDY; OVARY TUMOR; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77950472592     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.3617     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008
2. Ferlay J, Autier P, Boniol M, et al: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581-592, 2007
3. du Bois A, Quinn M, Thigpen T, et al: 2004 consensus statements on the management of ovarian cancer: Final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 16:viii7-viii12, 2005 (suppl 8)
4. Goff BA, Matthews BJ, Larson EH, et al: Predictors of comprehensive surgical treatment in patients with ovarian cancer. Cancer 109:2031-2042, 2007 (Pubitemid 46744198)
5. Earle CC, Schrag D, Neville BA, et al: Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 98:172-180, 2006 (Pubitemid 43205479)
6. Bristow RE, Tomacruz RS, Armstrong DK, et al: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 20:1248-1259, 2002 (Pubitemid 34177431)
7. du Bois A, Reuss A, Pujade-Lauraine E, et al: Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer 115:1234-1244, 2009
8. Winter WE 3rd, Maxwell GL, Tian C, et al: Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 25:3621-3627, 2007 (Pubitemid 47372600)
9. Harter P, Gnauert K, Hils R, et al: Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Int J Gynecol Cancer 17:1238-1244, 2007 (Pubitemid 350077354)
10. Morice P, Joulie F, Camatte S, et al: Lymph node involvement in epithelial ovarian cancer: Analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg 197:198-205, 2003 (Pubitemid 36927382)
11. Maggioni A, Benedetti-Panici P, Dell'Anna T, et al: Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer 95:699-704, 2006 (Pubitemid 44373484)
12. Panici BP, Maggione A, Hacker N, et al: Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: A randomized clinical trial. J Natl Cancer Inst 97:560-566, 2005 (Pubitemid 40723783)
13. Trimbos JB, Vergote I, Bolis G, et al: Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 95:113-125, 2003 (Pubitemid 36193260)
14. Chan JK, Munro EG, Cheung MK, et al: Association of lymphadenectomy and survival in stage I ovarian cancer patients. Obstet Gynecol 109:12-19, 2007 (Pubitemid 46043192)
15. Morice P, Joulie F, Rey A, et al: Are nodal metastases in ovarian cancer chemoresistant lesions? Analysis of nodal involvement in 105 patients treated with preoperative chemotherapy. Eur J Gynaecol Oncol 25:169-174, 2004 (Pubitemid 38268690)
16. Chambers SK: Systematic lymphadenectomy in advanced epithelial ovarian cancer: Two decades of uncertainty resolved. J Natl Cancer Inst 97:548-549, 2005
17. Spirtos NM, Gross GM, Freddo JL, et al: Cytoreductive surgery in advanced epithelial ovarian cancer of the ovary: The impact of aortic and pelvic lymphadenectomy. Gynecol Oncol 56:345-352, 1995
18. Pereira A, Magrina JF, Rex V, et al: Pelvic and aortic lymph node metastasis in epithelial ovarian cancer. Gynecol Oncol 67:10214-10221, 2007
19. Tangjitgamol S, Manusirivithaya S, Sheanakul C, et al: Can we rely on the size of lymph node in determining nodal metastases in ovarian cancer? Int J Gynecol Cancer 13:297-302, 2003
20. Aletti GD, Dowdy S, Podratz KC, et al: Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer. Am J Obstet Gynecol 195:1862-1868, 2006
21. di Re F, Baiocchi G, Fontanelli R, et al: Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: Prognostic significance of node metastases. Gynecol Oncol 62:360-365, 1996 (Pubitemid 26322426)
22. Scarabelli C, Gallo A, Visentin MC, et al: Systematic pelvic and para-aortic lymphadenectomy in advanced ovarian cancer patients with no residual intraperitoneal disease. Int J Gynecol Cancer 7:18-26, 1997 (Pubitemid 27010013)
23. Crawford SC, Vasey PA, Paul J, et al: Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial. J Clin Oncol 23:8802-8811, 2005 (Pubitemid 46211526)
24. Chan JK, Urban R, Hu JM, et al: The potential therapeutic role of lymph node resection in epithelial ovarian cancer: A study of 13,918 patients. Br J Cancer 96:1817-1822, 2007
25. du Bois A, Lück HJ, Meier W, et al: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320-1329, 2003
26. du Bois A, Weber B, Rochon J, et al: Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: A prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol 24:1127-1135, 2006
27. Pfisterer J, Weber B, Reuss A, et al: Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: A gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 98:1036-1045, 2006 (Pubitemid 44288151)
28. Cliby WA, Aletti GD, Wilson TO, et al: Is it justified to classify patients to stage IIIC epithelial ovarian cancer based on nodal involvement only? Gynecol Oncol 103:797-801, 2006